Project Grant R43AG056208

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This Project Grant award of $2,683,965.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund the development and optimization of an "all-human cellular system" for studying Alzheimer's disease (AD) and age-related dementias (ADRDs). The primary objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into a...

The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $472,695 project grant to 3D Bioanalytix, Inc. to develop a blood-based diagnostic test for early detection and differentiation of neurodegenerative diseases such as Alzheimer's and Parkinson's. The project leverages the company's Covalent Protein Painting (CPP) platform technology to detect and identify misfolded protein aggregates that characterize these diseases. This novel...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $509,038 to Ceiba Bio Inc. to develop a blood-based "exercise mimetic" treatment for Alzheimer's disease and related dementias. The project aims to identify and characterize recombinant human GPLD1 (a protein induced by exercise) as a potential therapeutic to confer the neurogenic and cognitive benefits of physical activity to Alzheimer's patients, who often face physical...

This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...

This $9,082,796 project grant was awarded by the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) federal grant program. The grant will fund a two-part clinical trial to be conducted by Banner Health's Banner Research Institute in Phoenix, AZ. The trial will evaluate the efficacy of a plaque-clearing antibody (PCA) treatment and a gamma secretase modulator (GSM) treatment, either alone or in combination, in reducing brain amyloid levels and slowing disease progression...

This $3.6 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research at the Icahn School of Medicine at Mount Sinai directed at understanding the role of glial cell interactions surrounding amyloid plaques in the progression of Alzheimer's disease. As part of the Aging Research program (CFDA 93.866), the three-year award will support investigation of how deletion of the Plexin-B1 gene impacts glial network formation and the...

This Project Grant award of $353,391.00, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to validate the use of a "Personal Learning Curve" paradigm as a sensitive marker of early memory decline related to Alzheimer's disease (AD) biomarkers in a large, diverse sample of older adults. The study seeks to determine if this digital cognitive assessment tool, which measures learning over repeated evaluations, can detect subtle AD-related memory failures...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...